Tanox was a biopharmaceutical company based in Houston, Texas. The company was founded by two biomedical research scientists, Nancy T. Chang and Tse Wen Chang in March 1986 …

Talizumab (TNX-901) is a humanized monoclonal antibody that was under development by Tanox in Houston, Texas as a new-concept therapeutic for allergic diseases.

2007年8月3日 · Genentech Inc. said Thursday that it has completed the $919 million acquisition of Tanox Inc., its partner in the development of the asthma drug Xolair, with the expiration of a …

2007年1月16日 · Tanox’s lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral activity in Phase 2 clinical testing. …

Tanox, Inc. is a a biotechnology company, engages in the discovery and development of therapeutic monoclonal antibodies.

Tanox is a biotechnology company specializing in the development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, …

2018年12月15日 · Tanox, Inc. is a biotechnology company engaged in the development of monoclonal antibodies that treat unmet medical needs related to asthma, allergy, …

2007年8月3日 · Genentech says it has completed its $919 million acquisition of US monoclonal antibody specialist Tanox, which gives the biotechnology gaining access to several drugs, …

Genentech, Novartis and Tanox have co-developed Genentech's anti-IgE humanized monoclonal antibody omalizumab for the treatment of allergic rhinitis and asthma. The antibody is currently …

2006年11月9日 · Genentech, Inc. and Tanox, Inc. today announced plans for Genentech to acquire Tanox, a biotechnology company specializing in the discovery and development of …